A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy
Condition: Cervical Cancer Intervention: Drug: HLX10+Albumin-Bound Paclitaxel Sponsor: Shanghai Henlius Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abraxane | Biotechnology | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Research | Study | Toxicology